ASCO 2020：11项近现代研究入选口头报告，17项Poster报告

均受全球性新冠疫情影响，原定于5月29日~6月2日在波士顿闭幕的旧金山药理学常务理事（ASCO）年会今年将首次以该线上基本上举办活动，这是目前为止最大规模的该线上盛会。今天，内阁会议的内容可题目公布，共103个sessions，里国共有11项研究工作入围口头报告，17项入围Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡洛替尼加卡培他滨使用HER2+心肌梗死乳腺胰脏（PHOEBE）：一项III期随机次测试。

三场：心肌梗死乳腺胰脏

编者：里国医学科学院诊所徐兵河大学教授、马飞大学教授，清华大学另有诊所胡夕春大学教授等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可疗程三阴性乳腺胰脏标准用药后卡培他滨维持快节奏肌肉注射的III期次测试（SYSUCC-001）。

三场：乳腺胰脏—大面积/地区/常规用药

编者：里山大学保健里心称王树森大学教授等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

为了让心肌梗死脑干的表型特征来数据分析脑干脊液里循环DNA探测的概率: 新工具对抗老对手

三场：新工具解决老解决办法

编者：李美芹 李德兰等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为里后期肝细胞会胰脏的前沿用药：一项对外开放页面、随机、多里心II/III期次测试。

三场：腹腔肠道胰脏—腹腔输尿管、十二指肠和实无

编者：四川大学华西诊所毕锋大学教授、里国人民解放军海军二七诊所秦叔逵大学教授等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国里后期肝胰脏病患阿帕替尼二该线用药：一项随机、口服折衷、实证III期研究工作

三场：腹腔肠道胰脏—腹腔输尿管、十二指肠和实无

编者：里国人民解放军海军二七诊所秦叔逵大学教授、四川大学华西诊所李秋大学教授等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

里后期开刀性卵巢胰脏二次细胞会减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

专刊：针灸胰脏症

编者：清华大学另有里山诊所臧荣余大学教授等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治性子宫抽脂后常规用药里的序贯放肌肉注射对比之外放疗或连动放肌肉注射（STARS研究工作）：一项随机、折衷、对外开放页面的III期次测试。

内阁会议：针灸胰脏症

编者：里山大学保健里心苍大学教授、刘继红大学教授等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比肌肉注射使用可切除的EGFR突变的N1-N2期NSCLC-随机III期药理学次测试的就此大体上生存研究。

专刊：心肌梗塞—非小细胞会大面积-地区/小细胞会/其他胸部

编者：广东省人民诊所吴一龙大学教授等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡集里于非小细胞会心肌梗塞病患前沿酪氨酸磷酸化类固醇建立联系或不建立联系积极的部队大面积放疗：III期对外开放页面药理学随机次测试（SINDAS）的里期结果（NCT02893332）。

专刊：心肌梗塞-非小细胞会集里于

编者：四川省人民诊所曾铭大学教授等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对一般而言丧命-1（PD-1）的人源化IgG4单克隆抗体建立联系阿昔替尼使用心肌梗死黏膜胃癌病患的Ib期研究工作的总生存期和人类圣万研究。

专刊：胃癌/皮肤胰脏

编者：华东师范大学诊所郭军、盛锡楠大学教授等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可用性和结果：通用CAR-T细胞会首次生理次测试用药开刀/难治性T细胞会急性红细胞会帕金森氏症（r/r T-ALL）的可用性和。内阁会议：开发里的用药技术开发-免疫用药。编者：称王立马等内容可：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利嘌呤在里后期输尿管柱状细胞会胰脏病患里的应用：一项随机的对外开放页面II期次测试（ORIENT-2）。内阁会议：腹腔肠道胰脏-腹腔输尿管胰脏、十二指肠胰脏和实无道胰脏编者：徐建明大学教授等内容可：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T细胞会对髓母细胞会瘤的消除性用药内阁会议：里枢神经系统编者：代红久、孙斌、杨东、徐晖、潘美美、魏佳、徐旭东内容可：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在里后期错配修复缺陷病患里的应用内阁会议：开发里的用药学-免疫用药编者：沈琳大学教授等内容可：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 继发性CD7-CART用药开刀/难治性ACUTE红细胞会帕金森氏症/帕金森氏症的首例生理药理学次测试内阁会议: 开发性用药学-免疫用药编者简介：张明志，杨林等内容可：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）建立联系应使用里后期实体瘤病患的Ib期研究工作内阁会议：发展性用药学；还有分子靶向药物和微人类学编者：龚继芳，沈琳大学教授等内容可：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin建立联系紫杉醇和nedaplatin用药开刀性或心肌梗死输尿管柱状细胞会胰脏（ESCC）病患的II期研究工作。内阁会议：腹腔肠道胰脏-腹腔输尿管、十二指肠和实无道胰脏的研究工作编者：称王志弱，李玉红，称王德申，称王凤华，任超，谭琼 称王志弱、李玉红、称王德深、称王凤华、任超、谭琼内容可：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁会议：腹腔肠道胰脏-腹腔输尿管胰脏、十二指肠胰脏和实无管胰脏的二该线用药编者：宋艳等内容可：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种肾脏外体放射状RNA特征向量使用初始前列腺时探测高等级胰脏的肾脏外体放射状RNA特征向量：一项多里心的回顾性研究工作内阁会议：泌尿生殖系统胰脏症；还有-胰脏、睾丸胰脏和胰脏编者简介：Liaoyuan Li等内容可：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积里后期宫颈胰脏并发肌肉注射后的常规肌肉注射内阁会议: 针灸胰脏症编者简介： 李珉珉等内容可：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药甲状腺髓性胰脏的相关性：基于ALTER01031次测试的研究。会话：头颈部编者：沈阳市诊所霸道大学教授内容可：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年纪对安洛替尼用药后病患结局的影响: ALTER01031的亚组研究内阁会议：头颈部编者：沈阳市诊所霸道大学教授内容可：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA研究数据分析I-IIIA期非小细胞会心肌梗塞（NSCLC）病患术后开刀: GASTO1035和GASTO1018的结果内阁会议：心肌梗塞-非小细胞会大面积-地区性/小细胞会/小细胞会/其他胸科胰脏症编者：Si-Yu Wang等内容可：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞会心肌梗塞（NSCLC）里EGFR酪氨酸磷酸化类固醇的新型乙型肝炎机制内阁会议:心肌梗塞-非小细胞会心肌梗死心肌梗塞编者简介：徐昕，金玲玲，满宇，欧真假，华宝，薛武，杨少，范敏 徐昕、金玲玲、满宇、欧真假、华宝、薛武、杨绍、范敏内容可：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试里里后期胃癌总生存的替代终点内阁会议：胃癌/皮肤胰脏编者：聂润聪，袁书弱，李元芳，陈英波，周志伟 聂润聪、袁书弱、李元芳、陈英波、周志伟内容可：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药开刀或心肌梗死继发性恶性颚骨病患的II期研究工作内阁会议： 帕金森氏症编者：唐丽娜，牛晓辉，李先念，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、称王振、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在里后期帕金森氏症病患多该线用药里的可用性和。内阁会议：帕金森氏症编者：姚伟涛，称王家弱，张鹏，称王欣，杜新辉，田志浩，牛晓颖 姚伟涛、称王家弱、张鹏、称王鑫、杜鑫辉、田志超、牛晓英内容可：11526宣传品：414